Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dara L Aisner

Showing results (71-80 of 130) with videos related to

Pageof 13
Sort By:
Journal of Neuropathology and Experimental Neurology|June 18, 2015
KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic AstrocytomasAline Paixão Becker, Cristovam Scapulatempo-Neto, Adriana C Carloni, et al.
Archives of Pathology & Laboratory Medicine|September 10, 2016
Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado ExperienceDara L Aisner, Mathew D Rumery, Daniel T Merrick, et al.
Cancer|January 28, 2012
Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancerRobert C Doebele, Xian Lu, Christopher Sumey, et al.
Clinical Lung Cancer|December 21, 2019
Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung CancerTejas Patil, Rao Mushtaq, Sydney Marsh, et al.
Clinical Lung Cancer|May 28, 2026
High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase InhibitorsYunan Nie, Alyse Staley, Trista K Hinz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2012
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancerRobert C Doebele, Amanda B Pilling, Dara L Aisner, et al.
Plos One|December 19, 2013
Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancerKurtis D Davies, Sakshi Mahale, David P Astling, et al.
Cancer Discovery|July 29, 2015
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101Robert C Doebele, Lara E Davis, Aria Vaishnavi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2012
Identifying and targeting ROS1 gene fusions in non-small cell lung cancerKurtis D Davies, Anh T Le, Mariana F Theodoro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 9, 2019
Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium ExperienceBadi El Osta, Madhusmita Behera, Sungjin Kim, et al.
Pageof 13

Showing results (71-80 of 130) with videos related to

Sort By:
Pageof 13
Journal of Neuropathology and Experimental Neurology|June 18, 2015
KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic AstrocytomasAline Paixão Becker, Cristovam Scapulatempo-Neto, Adriana C Carloni, et al.
Archives of Pathology & Laboratory Medicine|September 10, 2016
Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado ExperienceDara L Aisner, Mathew D Rumery, Daniel T Merrick, et al.
Cancer|January 28, 2012
Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancerRobert C Doebele, Xian Lu, Christopher Sumey, et al.
Clinical Lung Cancer|December 21, 2019
Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung CancerTejas Patil, Rao Mushtaq, Sydney Marsh, et al.
Clinical Lung Cancer|May 28, 2026
High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase InhibitorsYunan Nie, Alyse Staley, Trista K Hinz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2012
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancerRobert C Doebele, Amanda B Pilling, Dara L Aisner, et al.
Plos One|December 19, 2013
Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancerKurtis D Davies, Sakshi Mahale, David P Astling, et al.
Cancer Discovery|July 29, 2015
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101Robert C Doebele, Lara E Davis, Aria Vaishnavi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2012
Identifying and targeting ROS1 gene fusions in non-small cell lung cancerKurtis D Davies, Anh T Le, Mariana F Theodoro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 9, 2019
Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium ExperienceBadi El Osta, Madhusmita Behera, Sungjin Kim, et al.
Pageof 13